Health Watch: Wellness, Research & Healthy Living Tips
- Medication helps but is rarely sufficient; combine GLP-1 therapy with sustained behavioural change for durable outcomes.
- Best results arise when drugs are integrated into structured medical programmes supporting diet, physical activity, sleep, and muscle preservation.
- Food culture and wide availability of processed, addictive foods drive obesity; education, public information, and regulation are needed.
- Access, cost, and eligibility concerns persist; effective medicines like Mounjaro can be expensive and limited for many patients.
Your editorial (15 March) is right to highlight the growing evidence that GLP-1 medicines influence the brain’s reward systems and may have potential in treating addiction. These drugs represent an important therapeutic advance, and the moralising that has historically surrounded obesity treatment is both unhelpful and scientifically outdated. However, in clinical practice it is also clear that medication alone is rarely the whole answer.
Obesity, like addiction, involves powerful biological drivers such as appetite signalling, reward pathways and metabolic adaptation, but it also unfolds within behavioural and environmental contexts. Patients who achieve the most durable outcomes are typically those who combine pharmacological treatment with meaningful changes in diet quality, physical activity, sleep and muscle preservation.
The risk of the current debate is that it becomes polarised between two unhelpful extremes: the outdated belief that weight management is simply a matter of willpower, and the equally simplistic idea that a drug injection alone can solve a complex chronic condition.
GLP-1 medicines are remarkable tools, but the best results occur when they are integrated into structured medical programmes that support long-term behavioural change. In other words, biology matters, but biology is not the whole story.
Dr Sam Robson
Temple Clinic, Aberdeen
Your editorial is spot on. Food is as addictive as any drug, which I am compelled to use several times each day in a life bombarded with social encouragements and media-wide adverts. Until recently, I would at least keep fit and burn some off with daily vigorous exercise. Now my lower joints have worn out and I can tell that my proportion of muscle to fat has changed.
After 40 years of unsuccessful attempts to control my increasing weight, three months ago I started with Mounjaro. My GP was against it: the drugs are expensive, in short supply and while I am overweight, with a BMI of 28.5, I’m not obese. Others have a greater need, he said. He meant well. I have lost a stone for about £600, offset by reduced food costs and reduced stresses on my joints.
Name and address supplied
While I absolutely agree about the moralising around obesity and weight-loss drugs, the real problem is the food culture we are surrounded by. You only have to go into a supermarket to see why so many people are obese and suffer from ill health.
Shelves are full of manufactured food products, many of which contain an addictive mix of sugar, salt and fat now considered harmful to health. They far outweigh the space allotted to ingredients for cooking from scratch. Until there is a sea change in food culture involving better education and public information, and potentially including legislative controls of some kind, weight-loss jabs may operate as a distraction from the real problem.
Anne Williams
London
Your editorial is right to reframe obesity as an addiction driven by commercial determinants that therefore will need treatments including medicines. However, it is a shame that you didn’t extend the argument to nicotine dependence. Globally, the highly effective medicines to treat nicotine dependence such as varenicline and cytisine, as well as nicotine replacement products, are unavailable to many. We need the equivalent vision and regulation of the “tobacco-free generation” for unhealthy food.
Siân Williams
London
Read the full article on the original source


